TG Therapeutics, Inc. (0VGI.L)
USD 32.28
(-6.35%)
USD 32.28
(-6.35%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 39.82 Million USD | 0.0% |
| 2022 | - USD | 100.0% |
| 2021 | -23.6 Million USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 9.69 Million USD | 21.95% |
| 2017 | 7.94 Million USD | 42.04% |
| 2016 | 5.59 Million USD | 134.89% |
| 2015 | -16.03 Million USD | -363.17% |
| 2014 | 6.09 Million USD | 290.25% |
| 2013 | -3.2 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | -100.0% |
| 2010 | 4408.00 USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 81.24 Million USD | 4.53% |
| 2024 Q1 | 77.71 Million USD | 95.16% |
| 2023 Q3 | 33.55 Million USD | 10.98% |
| 2023 Q2 | 30.23 Million USD | 11.07% |
| 2023 FY | 39.82 Million USD | 0.0% |
| 2023 Q4 | 39.82 Million USD | 18.69% |
| 2023 Q1 | 27.22 Million USD | 0.0% |
| 2022 FY | - USD | 100.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q1 | 4.09 Million USD | 117.34% |
| 2022 Q2 | -32.45 Million USD | -893.04% |
| 2022 Q3 | - USD | 100.0% |
| 2021 Q2 | -5.02 Million USD | -189.96% |
| 2021 Q3 | -13.5 Million USD | -168.58% |
| 2021 Q4 | -23.6 Million USD | -74.75% |
| 2021 FY | -23.6 Million USD | 0.0% |
| 2021 Q1 | 5.59 Million USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | - USD | -100.0% |
| 2018 Q1 | 6.82 Million USD | -14.13% |
| 2018 FY | 9.69 Million USD | 21.95% |
| 2018 Q4 | 9.69 Million USD | -14.91% |
| 2018 Q3 | 11.38 Million USD | 29.38% |
| 2018 Q2 | 8.8 Million USD | 29.0% |
| 2017 Q3 | - USD | -100.0% |
| 2017 Q2 | 9.66 Million USD | 15.03% |
| 2017 Q1 | 8.39 Million USD | 50.13% |
| 2017 Q4 | 7.94 Million USD | 0.0% |
| 2017 FY | 7.94 Million USD | 42.04% |
| 2016 Q4 | 5.59 Million USD | -44.12% |
| 2016 Q3 | 10.01 Million USD | -30.99% |
| 2016 Q2 | 14.51 Million USD | 32.16% |
| 2016 Q1 | 10.97 Million USD | 168.46% |
| 2016 FY | 5.59 Million USD | 134.89% |
| 2015 Q4 | -16.03 Million USD | -261.17% |
| 2015 FY | -16.03 Million USD | -363.17% |
| 2015 Q1 | 9.72 Million USD | 59.51% |
| 2015 Q2 | 10.92 Million USD | 12.35% |
| 2015 Q3 | 9.95 Million USD | -8.89% |
| 2014 Q2 | -2.2 Million USD | -191.29% |
| 2014 Q1 | 2.41 Million USD | 175.52% |
| 2014 Q4 | 6.09 Million USD | -32.76% |
| 2014 FY | 6.09 Million USD | 290.25% |
| 2014 Q3 | 9.06 Million USD | 510.46% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | -3.2 Million USD | 0.0% |
| 2013 Q4 | -3.2 Million USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | -100.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | -100.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | 4408.00 USD | 0.0% |
| 2010 Q4 | 4408.00 USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Editas Medicine, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 53.29 Million USD | 25.271% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 48.554% |
| Perrigo Company plc | 1.14 Billion USD | 96.51% |
| Illumina, Inc. | 587 Million USD | 93.216% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.217% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -283.947% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.521% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 42.11 Million USD | 5.431% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 98.457% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 516.23 Million USD | 92.286% |
| Biogen Inc. | 2.52 Billion USD | 98.424% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -262.093% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -1311.663% |
| bluebird bio, Inc. | 22.91 Million USD | -73.755% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 39.315% |
| FibroGen, Inc. | 41.56 Million USD | 4.191% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 96.137% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 55.328% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | 33.29% |
| Myriad Genetics, Inc. | 20.1 Million USD | -98.124% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 98.447% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 1729.419% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 89.68% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 96.403% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 94.61% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -40.099% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -310.293% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 16.1 Million USD | -147.332% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -163.119% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 87.666% |
| OPKO Health, Inc. | 65.69 Million USD | 39.384% |
| Exelixis, Inc. | 17.32 Million USD | -129.885% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -3.977% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -415.175% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 12.02 Million USD | -231.196% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 21.22 Million USD | -87.641% |
| Insmed Incorporated | 83.24 Million USD | 52.163% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 68.791% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -108.76% |
| Incyte Corporation | 62.97 Million USD | 36.761% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 87.892% |